Drug Patent Critic Hits Back At Claims Research Is Flawed
A nonprofit that has alleged patents lead to high drug prices has defended its methods after the Senate intellectual property subcommittee's top Republican said its research was flawed....To view the full article, register now.
Already a subscriber? Click here to view full article